1. Amyris (NASDAQ:AMRS) popped on Monday with good volume, gaining 81 cents, or 30%, to 3.49, after reaching a session high of 3.70, on 6.4 million shares traded. It broke out across the base pattern in the 2.90 zone, and it looks like that pattern could take it to the 4.00 range, which is near-term resistance and scalp target, to reach 5.35-5.50.
2. Cytokinetics (NASDAQ:CYTK) exploded on big volume on Monday with a breakaway gap, across double-tops, jumping 5.23, or 33%, to 20.99, with a multi-week and session high of 21.69, on 5.9 million shares traded and another 28 cents in after-hours. The way the angle is drawn, we could see a mid-20’s stock here.
3. Dicerna Pharmaceuticals (NASDAQ:DRNA) broke through an inverse head and shoulders on Monday and took out the neckline, popping 3.51, or 16.8%, to 24.35, with a high of 24.47, on 850,953 shares traded. Most probably, it will move up to 28.
4. LexinFintech Holdings (NASDAQ:LX) was a nice pick on Monday, with a declining topsline and close above the 50-day, just beneath resistance, ramping 1.31, or 17% to 9.00, not far off the session high of 9.06, on 2.2 million shares traded. Keep an eye on this one on Tuesday. If it gets above 9 1/4, this could be 10 1/2, even 11 1/4 stock.
5. Moderna (NASDAQ:MRNA) made a fantastic move on Monday. In April it formed a triple-top, then exploded, formed a little flag, and popped three days in a row, going from 46 to 67. On Monday when it popped it moved up 7.65, or 13%, to 66.90, with a multi-week and session high of 67.67, on 34.85 million shares traded. It looks higher. I think mid-to-high 70’s is the target.
6. Vapotherm (NYSE:VAPO) popped sharply last week and pulled back for two days, it had an inside day on Friday, and on Monday, it popped again, moving up 1.87, or 7%, to 28.88, with a high of 29.94, on 754,406 shares traded. The target going forward is 34.
Stocks on the long side
Abeona Therapeutics Inc. (NASDAQ:ABEO), Akebia Therapeutics, Inc. (NASDAQ:AKBA), Amyris, Inc. (AMRS), Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), Adhera Therapeutics, Inc. (ATRX), AVEO Pharmaceuticals, Inc. (AVEO), BioCryst (NASDAQ:BCRX) Pharmaceuticals, Inc. (BCRX), Bellerophon (NASDAQ:BLPH) Therapeutics, Inc. (BLPH), BioSig Technologies, Inc. (NASDAQ:BSGM), Capricor Therapeutics, Inc. (NASDAQ:CAPR), Co-Diagnostics, Inc. (NASDAQ:CODX), Cytokinetics, Incorporated (CYTK), Dicerna Pharmaceuticals, Inc. (DRNA), Exelixis, Inc. (NASDAQ:EXEL), Fluidigm Corporation (NASDAQ:FLDM), InMode Ltd. (NASDAQ:INMD), Direxion Daily S&P (NYSE:SPY) Biotech Bull 3X Shares (LABU), LexinFintech Holdings Ltd. (LX), MacroGenics, Inc. (NASDAQ:MGNX), Moderna, Inc. (MRNA), NanoViricides, Inc. (NNVC), Novavax, Inc. (NASDAQ:NVAX), Puma Biotechnology, Inc. (NASDAQ:PBYI), Quidel Corporation (NASDAQ:QDEL), Quotient Limited (NASDAQ:QTNT), SmileDirectClub, Inc. (NASDAQ:SDC), Schrodinger, Inc. (NASDAQ:SDGR), Teladoc Health, Inc. (NYSE:TDOC), Vapotherm, Inc. (VAPO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Vaxart, Inc. (NASDAQ:VXRT), ZOOM Technologies, Inc. (ZOOM), and Zynex, Inc. (NASDAQ:ZYXI).